%0 Journal Article
%T Molecular design of peptide therapeutics via N-terminal modification.
%A Sürmeli D
%A Dinsmore TC
%A Anchukaitis HM
%A Montanari V
%A Beinborn M
%A Kumar K
%J Methods Enzymol
%V 698
%N 0
%D 2024
%M 38886032
%F 1.682
%R 10.1016/bs.mie.2024.04.011
%X Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon are three naturally occurring peptide hormones that mediate glucoregulation. Several agonists representing appropriately modified native ligands have been developed to maximize metabolic benefits with reduced side-effects and many have entered the clinic as type 2 diabetes and obesity therapeutics. In this work, we describe strategies for improving the stability of the peptide ligands by making them refractory to dipeptidyl peptidase-4 catalyzed hydrolysis and inactivation. We describe a series of alkylations with variations in size, shape, charge, polarity, and stereochemistry that are able to engender full activity at the receptor(s) while simultaneously resisting enzyme-mediated degradation. Utilizing this strategy, we offer a novel method of modulating receptor activity and fine-tuning pharmacology without a change in peptide sequence.